Esperion Therapeutis.Inc. buy StockNews.com
Start price
26.10.24
/
50%
€1.93
Target price
26.10.25
-
Performance (%)
18.51%
End price
27.10.25
€2.29
Summary
This prediction ended on 27.10.25 with a price of €2.29. The prediction had a final performance of 18.51%. StockNews_com has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
AI-generated
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Esperion Therapeutis.Inc. | - | - | - |
| iShares Core DAX® | -1.586% | 5.028% | 6.332% |
| iShares Nasdaq 100 | -4.148% | -0.125% | 25.735% |
| iShares Nikkei 225® | -6.302% | 0.528% | 41.384% |
| iShares S&P 500 | -3.225% | 0.470% | 20.449% |
Comments by StockNews_com for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
Esperion Therapeutics, Inc. (NASDAQ: ESPR) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for ESPR provided by MarketBeat
In the thread Trading Esperion Therapeutis.Inc.
Die von StockNews_com gewählte maximale Laufzeit wurde überschritten
Stopped prediction by StockNews_com for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
Start price
Target price
Perf. (%)
€1.70
17.08.25
17.08.25
-
17.08.26
17.08.26
63.85%
18.08.26
18.08.26
Esperion Therapeutis.Inc.
Start price
Target price
Perf. (%)
€1.97
05.10.24
05.10.24
-
05.10.25
05.10.25
41.81%
06.10.25
06.10.25